Delivery of AAV-IGF-1 to the CNS Extends Survival in ALS Mice Through Modification of Aberrant Glial Cell Activity

Dodge, James C.; Haidet, Amanda M.; Yang, Wendy; Passini, Marco A.; Hester, Mark; Clarke, Jennifer; Roskelley, Eric M.; Treleaven, Christopher M.; Rizo, Liza; Martin, Heather; Kim, Soo H.; Kaspar, Rita; Taksir, Tatyana V.; Griffiths, Denise A.; Cheng, Seng H.; Shihabuddin, Lamya S.; Kaspar, Brian K.
June 2008
Molecular Therapy;Jun2008, Vol. 16 Issue 6, p1056
Academic Journal
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of the motor system. Recent work in rodent models of ALS has shown that insulin-like growth factor-1 (IGF-1) slows disease progression when delivered at disease onset. However, IGF-1's mechanism of action along the neuromuscular axis remains unclear. In this study, symptomatic ALS mice received IGF-1 through stereotaxic injection of an IGF-1-expressing viral vector to the deep cerebellar nuclei (DCN), a region of the cerebellum with extensive brain stem and spinal cord connections. We found that delivery of IGF-1 to the central nervous system (CNS) reduced ALS neuropathology, improved muscle strength, and significantly extended life span in ALS mice. To explore the mechanism of action of IGF-1, we used a newly developed in vitro model of ALS. We demonstrate that IGF-1 is potently neuroprotective and attenuates glial cell–mediated release of tumor necrosis factor-α (TNF-α) and nitric oxide (NO). Our results show that delivering IGF-1 to the CNS is sufficient to delay disease progression in a mouse model of familial ALS and demonstrate for the first time that IGF-1 attenuates the pathological activity of non-neuronal cells that contribute to disease progression. Our findings highlight an innovative approach for delivering IGF-1 to the CNS.Molecular Therapy (2008) 16 6, 1056–1064 doi:10.1038/mt.2008.60


Related Articles

  • Neurodegenerative diseases: As one door closes, another opens. Farley, Suzanne // Nature Reviews Drug Discovery;Aug2003, Vol. 2 Issue 8, p604 

    Each day, about fifteen people are diagnosed with amyotrophic lateral sclerosis (ALS) in the U. S. alone. Unfortunately, the size of the pharmaceutical armamentarium that is presently available for the treatment of this fatal neurodegenerative disease in no way reflects that of the patient...

  • Regulation of FMO and PON Detoxication Systems in ALS Human Tissues. Gagliardi, Stella; Abel, Kenneth; Bianchi, Marika; Milani, Pamela; Bernuzzi, Stefano; Corato, Manuel; Ceroni, Mauro; Cashman, John; Cereda, Cristina // Neurotoxicity Research;May2013, Vol. 23 Issue 4, p370 

    Amyotrophic lateral sclerosis (ALS) is an adult-onset, progressive, and fatal neurodegenerative disease with unknown etiology. Recent evidence suggests an association between the exposure to toxic environmental factors and sporadic ALS. The flavin-containing monooxygenases (FMOs) and paraoxonase...

  • Mitochondrial Network Genes in the Skeletal Muscle of Amyotrophic Lateral Sclerosis Patients. Bernardini, Camilla; Censi, Federica; Lattanzi, Wanda; Barba, Marta; Calcagnini, Giovanni; Giuliani, Alessandro; Tasca, Giorgio; Sabatelli, Mario; Ricci, Enzo; Michetti, Fabrizio // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Recent evidence suggested that muscle degeneration might lead and/or contribute to neurodegeneration, thus it possibly play a key role in the etiopathogenesis and progression of amyotrophic lateral sclerosis (ALS). To test this hypothesis, this study attempted to categorize functionally relevant...

  • A Novel Acylaminoimidazole Derivative, WN1316, Alleviates Disease Progression via Suppression of Glial Inflammation in ALS Mouse Model. Tanaka, Kazunori; Kanno, Takuya; Yanagisawa, Yoshiko; Yasutake, Kaori; Inoue, Satoshi; Hirayama, Noriaki; Ikeda, Joh-E // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Amyotrophic lateral sclerosis (ALS) is an adult-onset motor neuron degenerative disease. Given that oxidative stress and resulting chronic neuronal inflammation are thought to be central pathogenic, anti-oxidative agents and modulators of neuronal inflammation could be potential therapies for...

  • Damage control. Beyzarov, Elena Portyansky // Drug Topics;8/21/2000, Vol. 144 Issue 16, p24 

    Discusses the findings of a study which may have found a way to repair the nervous system. Information on growth hormone; Mechanism of action of an agent which delay onset of amyotrophic lateral sclerosis; Information on related studies.

  • Multiple system atrophy. Rehman, H. U. // Postgraduate Medical Journal;Jun2001, Vol. 77 Issue 908, p379 

    Multiple system atrophy (MSA) is a degenerative disease of the central nervous system. MSA is a sporadic disease. MSA was considered a rare disease but many patients with MSA are misdiagnosed as suffering from idiopathic Parkinson's disease. It is clear from a large postmortem series of...

  • The non-cell-autonomous component of ALS: new in vitro models and future challenges. Ferraiuolo, Laura // Biochemical Society Transactions;Oct2014, Vol. 42 Issue 5, p1270 

    Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder affecting the motor nerves. At present, there is no effective therapy for this devastating disease and only one Food and Drug Administration (FDA)-approved drug, riluzole, is known to moderately extend survival. In the...

  • MICB Gene Expression on Peripheral Blood Mononuclear Cells and Susceptibility to Multiple Sclerosis in North of Iran. Abediankenari, Saeid; Yousefzadeh, Yousef; Majidi, Mohammad; Ghasemi, Maryam; Nasehi, Mohammad Mahdi; Ghaffari, Javad; Saravi, Reza Habibi; Abedini, Mahmoud; Elyasi, Mitra // Iranian Journal of Allergy, Asthma & Immunology;2011, Vol. 10 Issue 4, p261 

    Multiple sclerosis (MS) is an autoimmune multifactorial degenerative disease with detrimental affliction on central nervous system. MHC class I chain- related geneA,B(MICA and MICB) are nonclassical human leukocyte antigens that can affect on some diseases and also on transplantation. The...

  • Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke. Maples, Kirk R.; Green, A. Richard; Floyd, Robert A. // CNS Drugs;2004, Vol. 18 Issue 15, p1071 

    At present, none of the neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and stroke are treatable with compounds that slow or halt neuronal cell death. However, the prototype nitrone radical trap alpha-phenyl-tert-butylnitrone (PBN) has been shown to be an effective...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics